Alcon bought Aerie Pharmaceuticals Aerie Pharmaceuticals from 11/22/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Alcon completed its acquisition of Aerie Pharmaceuticals for $770 million, or 15.25 per share.

Aerie Pharmaceuticals

Review

Source:

{source} pictogram

investor.alcon.com

Vladimir Petenev

News editor

Write your comment first

News feed

Arsagera reported for 2023 by RAS

4/1/24 ARSA

Ural Forge reported for 2023 by RAS

4/1/24 URKZ

DZRD reported for 2023 by RAS

4/1/24 DZRD

Abrau-Durso reported for 2023 by RAS

4/1/24 ABRD

Bank Kuznetsky reported for 2023 by RAS

4/1/24 KUZB

VSMPO-AVISMA partially reported for 2023 by RAS

4/1/24 VSMO

KuibyshevAzot reported for 2023 by IFRS

4/1/24 KAZT

NCSP reports for 2023 by IFRS

4/1/24 NMTP

MD Medical will allocate 50-75% of EBITDA to dividends

4/1/24 MDMG

Artgen reported for 2023 by RAS

4/1/24 ABIO